Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage III breast cancer disease, with histological confirmation by true-cut or open-biopsy.~* Ages between 18 and 75 years old. Patients older than 70 must have an adequate quality of life to be eligible.~* Patients cannot have received previous treatment with chemotherapy, hormone therapy, radiotherapy or immune therapy.~* Performance status of 0,1, 2 Eastern Cooperative Oncology Group (ECOG).~* At least a 6 month life expectancy.~* Neutrophils \> 1500; platelets \> 100000; haemoglobin \> 10 mg/dL.~* Adequate renal and hepatic functions, with serum creatinine \< 1.2 mg/dl and total bilirubin \< 2 mg/dl.~* Adequate contraceptive methods during the study and up to 3 months after.~* Adequate cardiac function assessed by physical exam, electrocardiogram and left ventricular ejection fraction \> 55%.~Exclusion Criteria:~* Inflammatory carcinoma or stage I, II or IV breast cancer disease.~* Males.~* Active infection.~* Other neoplasms except for basal skin carcinoma or cervical in situ carcinoma adequately treated. Other previous neoplasms are allowed if diagnosed and treated more than 5 years before study registration.~* Concomitant serious disease provoking organ failure (heart, renal, hepatic, respiratory).~* Pre-existing motor or sensorial neuropathy \> grade 1.~* Inability for treatment compliance.~* History of hypersensitivity to compounds such as cremophor, cyclosporine or vitamin K.~* History of arrhythmias or congestive heart failure, even when controlled; or active cardiac blocking of second or third grade.~* History of myocardial infarction in the previous 6 months.~* Hypertension not controlled.~* Pregnant or lactating women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Adriamycine + Paclitaxel (Type: EXPERIMENTAL): Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).